Drastop injection solution 100mg / ml, 2ml No. 10

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of the peripheral joints;

• intervertebral osteoarthritis and osteochondrosis.

The drug is administered intramuscularly in 1 ml (100 mg of chondroitin sodium sulfate) every other day. With good tolerance, the dose is increased to 2 ml (200 mg of chondroitin sodium sulfate), starting with the fourth injection. The course of treatment is 25-30 injections. If necessary, it is possible to carry out repeated courses of treatment after 6 months.

Solution for intramuscular injection is transparent, slightly yellowish.

1 ml chondroitin sodium sulfate 100 mg

Excipients: benzyl alcohol - 12 mg, 1% sodium hydroxide solution or 0.1M hydrochloric acid solution - up to pH 6.5-6.8, water d / i - up to 1 ml.

• Hypersensitivity to the components of the drug;

• bleeding, bleeding tendency;

• thrombophlebitis;

• childhood (efficacy and safety have not been established).

pharmachologic effect

It has a chondrostimulating, regenerating, anti-inflammatory and analgesic effect. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue. Has chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, subchondrial bone; inhibits enzymes that cause degradation (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes. It helps to reduce the release of inflammatory mediators and pain factors into the synovial fluid, suppresses the secretion of leukotrienes and prostaglandins. Slows down the resorption of bone tissue and reduces calcium loss, accelerates the processes of bone tissue regeneration. Chondroitin sulfate slows down the progression of osteoarthritis and osteochondrosis. Promotes the restoration of the joint capsule and cartilaginous surfaces of the joints,prevents the collapse of connective tissue, normalizes the production of articular fluid.

When using the drug, pain decreases and the mobility of the affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy. In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed within 2-3 weeks from the start of the course. Structurally similar to heparin, it can potentially prevent the formation of fibrin thrombi in the synovial and subchondrial microvasculature.

Pharmacokinetics

Suction

After i / m administration of chondroitin, sodium sulfate is easily absorbed. Within 30 minutes after injection, it is found in the blood in significant concentrations. Cmax of chondroitin sodium sulfate in plasma is achieved after 1 hour, then gradually decreases within 2 days.

Distribution

Chondroitin sodium sulfate accumulates mainly in the cartilage tissue that forms the joints. The synovium is not an obstacle to the penetration of the drug into the joint cavity. 15 minutes after the i / m injection of chondroitin, sodium sulfate is found in the synovial fluid, then penetrates into the articular cartilage, where its Cmax is reached after 48 hours.

Side effect

Allergic reactions: pruritus, erythema, urticaria, dermatitis, angioedema.

From the digestive system: dyspepsia.

Local reactions: pain and hemorrhages at the injection site.

Application during pregnancy and lactation

It is not recommended to use the drug during pregnancy. During treatment, breastfeeding should be discontinued due to lack of data.

special instructions

To achieve a stable clinical effect, at least 25 injections of the drug are required. The effect lasts for several months after the end of treatment. To prevent exacerbations, repeated courses of treatment are used.

In case of allergic reactions or hemorrhages, treatment should be discontinued.

Use in pediatrics

Data on the efficacy and safety of the drug Drastop in children are currently not described.

Influence on the ability to drive vehicles and mechanisms

Drastop does not affect the ability to drive vehicles and engage in potentially hazardous activities that require increased attention.

Overdose

Overdose is not described and is unlikely.

Drug interactions

It is possible to enhance the action of indirect anticoagulants, antiplatelet agents, fibrinolytics, which requires more frequent monitoring of blood coagulation indicators when used together.